Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainKRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib